Predictive Oncology (POAI) Competitors

Predictive Oncology (NASDAQ:POAI) and Nexalin Technology (NASDAQ:NXL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends.

Which has better earnings and valuation, POAI or NXL?

Nexalin Technology has lower revenue, but higher earnings than Predictive Oncology. Nexalin Technology is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.48M	5.17	-$13.98M	-$3.05	-0.37
Nexalin Technology	$168.72K	184.51	-$4.65M	-$0.82	-2.85

Which has more risk & volatility, POAI or NXL?

Predictive Oncology has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.33, indicating that its share price is 333% more volatile than the S&P 500.

Is POAI or NXL more profitable?

Predictive Oncology has a net margin of -1,012.32% compared to Nexalin Technology's net margin of -3,407.98%. Nexalin Technology's return on equity of -187.59% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-1,012.32%	-286.30%	-122.11%
Nexalin Technology	-3,407.98%	-187.59%	-167.21%

Do analysts recommend POAI or NXL?

Predictive Oncology currently has a consensus target price of $3.00, indicating a potential upside of 167.86%. Nexalin Technology has a consensus target price of $5.00, indicating a potential upside of 113.68%. Given Predictive Oncology's higher possible upside, research analysts clearly believe Predictive Oncology is more favorable than Nexalin Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nexalin Technology	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to POAI or NXL?

In the previous week, Predictive Oncology had 1 more articles in the media than Nexalin Technology. MarketBeat recorded 3 mentions for Predictive Oncology and 2 mentions for Nexalin Technology. Nexalin Technology's average media sentiment score of 2.00 beat Predictive Oncology's score of 0.78 indicating that Nexalin Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Predictive Oncology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nexalin Technology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do institutionals & insiders have more ownership in POAI or NXL?

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 0.6% of Nexalin Technology shares are owned by institutional investors. 3.4% of Predictive Oncology shares are owned by insiders. Comparatively, 24.0% of Nexalin Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Does the MarketBeat Community prefer POAI or NXL?

Predictive Oncology received 147 more outperform votes than Nexalin Technology when rated by MarketBeat users. However, 66.67% of users gave Nexalin Technology an outperform vote while only 64.22% of users gave Predictive Oncology an outperform vote.

Company	Underperform	Outperform
Predictive Oncology	Outperform Votes 149 64.22%	Underperform Votes 83 35.78%
Nexalin Technology	Outperform Votes 2 66.67%	Underperform Votes 1 33.33%

Summary

Nexalin Technology beats Predictive Oncology on 10 of the 18 factors compared between the two stocks.